Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
114.84
-1.16 (-1.00%)
Mar 4, 2025, 3:27 PM EST - Market open
Gilead Sciences Revenue
In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth. Gilead Sciences had revenue of $7.57B in the quarter ending December 31, 2024, with 6.40% growth.
Revenue (ttm)
$28.75B
Revenue Growth
+6.04%
P/S Ratio
5.03
Revenue / Employee
n/a
Employees
n/a
Market Cap
143.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
| Abbott Laboratories | 41.95B |
GILD News
- 1 hour ago - Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript) - Seeking Alpha
- 8 hours ago - Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025 - Invezz
- 1 day ago - Gilead Sciences sets aside $200 million to resolve HIV drug probe - Reuters
- 5 days ago - Why Gilead Sciences Remains A Buy After A 40% Rally - Seeking Alpha
- 7 days ago - MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead's Trodelvy® in Advanced Breast Cancer - Business Wire
- 8 days ago - European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention - Business Wire
- 11 days ago - Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis - Business Wire
- 12 days ago - Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire